Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

FDA warns that certain coronary imaging catheters are being removed from market over safety concerns
A catheter sheath detached during use and was left in the patient’s body. It was successfully removed, but the FDA said it is now evaluating the potential risk to others going forward. There is no official recall at this time.
Mediterranean diets that include some lean red meat can still boost cardiovascular health
The study's authors focused on blood pressure reductions and arterial stiffness, sharing their findings in Current Developments in Nutrition.
Late-breaking cardiovascular drug trials took center stage at ACC.25
Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.
‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes
Patients who present with type 2 diabetes and PAD often face substantial mobility issues. According to new data presented at ACC.25, however, treatment with semaglutide could represent a major step forward for this high-risk population.
Strokes more likely for U.S. heart transplant recipients following policy change
A nationwide policy shift implemented in 2018 was designed to, among other things, improve the waiting list mortality rate. One unintended consequence, however, is that patients are now more likely to experience a stroke after receiving a new heart.

Teaming Up to Treat Pulmonary Emboli: Clotbusters Illustrates Potential of Coordinated Response Programs

At one hospital, an aggressive treatment PE treatment program has dramatically reduced mortality.

Medtronic Unveils New Aortic and Peripheral Data from Two Late-Breaking Clinical Trials at VIVA 2015

Medtronic plc (NYSE: MDT) today announced new clinical data in interventional treatments for aortic and peripheral vascular diseases in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2015.

Vascular & Endovascular

FDA warns that certain coronary imaging catheters are being removed from market over safety concerns

Mediterranean diets that include some lean red meat can still boost cardiovascular health

Late-breaking cardiovascular drug trials took center stage at ACC.25

‘A practice-changing trial’: Semaglutide linked to key benefits for PAD patients with diabetes

Strokes more likely for U.S. heart transplant recipients following policy change